{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:45:58Z","timestamp":1789519558437,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K11260"],"award-info":[{"award-number":["JP16K11260"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated long-term treatment responses in patients with treatment-na\u00efve polypoidal choroidal vasculopathy (PCV) undergoing photodynamic therapy (PDT) with intravitreal ranibizumab (IVR). The medical charts of 14 patients with treatment-na\u00efve PCV who underwent PDT with IVR were retrospectively reviewed. Patients were followed up and treated with additional IVR for \u22653 years. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), greatest linear dimension (GLD) on angiography, polyp regression and central choroidal thickness (CCT) were assessed. Associations between these functional or anatomic outcomes with age, baseline CCT, baseline GLD or choroidal vascular hyperpermeability (CVH) were investigated using univariate and multivariate analysis. Mean logMAR BCVA improved significantly at 3 years (0.34\u2009\u00b1\u20090.24 to 0.12\u2009\u00b1\u20090.29, p\u2009=\u20090.003). Greater BCVA improvement and longer time to first recurrence was significantly associated with CVH. Fewer number of IVR retreatment within 3 years was associated with thicker baseline CCT. Mean CCT significantly decreased at 3 years (217\u2009\u00b1\u200933\u2009\u00b5m to 197\u2009\u00b1\u200948\u2009\u00b5m, p\u2009=\u20090.003). Greater decrease of CCT was significantly associated both with greater number of IVR retreatment within 3 years and absence of CVH. These results showed that pachychoroid characteristics at baseline was associated long-term functional and anatomic outcomes in patients with treatment-na\u00efve PCV who had undergone combination PDT and IVR.<\/jats:p>","DOI":"10.1038\/s41598-020-65346-w","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:02:32Z","timestamp":1589968952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"10","author":[{"given":"Keiko","family":"Azuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko Shimizu","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-4343","authenticated-orcid":false,"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"65346_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi, L. A., Sorenson, J., Spaide, R. F. & Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10, 1\u20138 (1990).","journal-title":"Retina"},{"key":"65346_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000360308","volume":"232","author":"S Honda","year":"2014","unstructured":"Honda, S. et al. Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy. Ophthalmologica 232, 92\u201396, https:\/\/doi.org\/10.1159\/000360308 (2014).","journal-title":"Ophthalmologica"},{"key":"65346_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko, I., Iida, T., Saito, M., Nagayama, D. & Saito, K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am. J. Ophthalmol. 144, 15\u201322, https:\/\/doi.org\/10.1016\/j.ajo.2007.03.047 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR4","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","volume":"121","author":"K Sho","year":"2003","unstructured":"Sho, K. et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch. Ophthalmol. 121, 1392\u20131396, https:\/\/doi.org\/10.1001\/archopht.121.10.1392 (2003).","journal-title":"Arch. Ophthalmol."},{"key":"65346_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10384-017-0556-3","volume":"62","author":"A Tsujikawa","year":"2018","unstructured":"Tsujikawa, A. et al. Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. Jpn. J. Ophthalmol. 62, 127\u2013136, https:\/\/doi.org\/10.1007\/s10384-017-0556-3 (2018).","journal-title":"Jpn. J. Ophthalmol."},{"key":"65346_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1097\/IAE.0b013e31820d3f28","volume":"31","author":"H Bessho","year":"2011","unstructured":"Bessho, H., Honda, S., Imai, H. & Negi, A. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up. Retina 31, 1598\u20131602, https:\/\/doi.org\/10.1097\/IAE.0b013e31820d3f28 (2011).","journal-title":"Retina"},{"key":"65346_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/s0002-9394(02)01404-6","volume":"133","author":"M Uyama","year":"2002","unstructured":"Uyama, M. et al. Polypoidal choroidal vasculopathy: natural history. Am. J. Ophthalmol. 133, 639\u2013648, https:\/\/doi.org\/10.1016\/s0002-9394(02)01404-6 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR8","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"WM Chan","year":"2004","unstructured":"Chan, W. M. et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 111, 1576\u20131584, https:\/\/doi.org\/10.1016\/j.ophtha.2003.12.056 (2004).","journal-title":"Ophthalmology"},{"key":"65346_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00006982-200210000-00001","volume":"22","author":"RF Spaide","year":"2002","unstructured":"Spaide, R. F. et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22, 529\u2013535 (2002).","journal-title":"Retina"},{"key":"65346_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ophtha.2007.10.018","volume":"115","author":"Y Tano","year":"2008","unstructured":"Tano, Y. & Ophthalmic, P. D. T. S. G. Guidelines for PDT in Japan. Ophthalmology 115, 585\u2013585 e586, https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.018 (2008).","journal-title":"Ophthalmology"},{"key":"65346_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","volume":"103","author":"N Miyamoto","year":"2019","unstructured":"Miyamoto, N. et al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br. J. Ophthalmol. 103, 844\u2013848, https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312419 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"65346_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","volume":"27","author":"Y Hirami","year":"2007","unstructured":"Hirami, Y. et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 27, 335\u2013341, https:\/\/doi.org\/10.1097\/01.iae.0000233647.78726.46 (2007).","journal-title":"Retina"},{"key":"65346_CR13","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh, A. et al. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 135, 1206\u20131213, https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"65346_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.pdpdt.2018.10.019","volume":"24","author":"L Liu","year":"2018","unstructured":"Liu, L., Hu, C., Chen, L. & Hu, Y. Photodynamic therapy for symptomatic circumscribed choroidal hemangioma in 22 Chinese patients: A retrospective study. Photodiagnosis Photodyn. Ther. 24, 372\u2013376, https:\/\/doi.org\/10.1016\/j.pdpdt.2018.10.019 (2018).","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"65346_CR15","doi-asserted-by":"publisher","first-page":"e110667","DOI":"10.1371\/journal.pone.0110667","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang, W., He, M. & Zhang, X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. Plos one 9, e110667, https:\/\/doi.org\/10.1371\/journal.pone.0110667 (2014).","journal-title":"Plos one"},{"key":"65346_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2013.11.015","volume":"157","author":"HM Kang","year":"2014","unstructured":"Kang, H. M., Koh, H. J., Lee, C. S. & Lee, S. C. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome. Am. J. Ophthalmol. 157, 598\u2013606 e591, https:\/\/doi.org\/10.1016\/j.ajo.2013.11.015 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR17","doi-asserted-by":"publisher","unstructured":"Miyata, M. et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol, https:\/\/doi.org\/10.1136\/bjophthalmol-2018-311963 (2018).","DOI":"10.1136\/bjophthalmol-2018-311963"},{"key":"65346_CR18","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1111\/aos.12110","volume":"91","author":"A Kawamura","year":"2013","unstructured":"Kawamura, A., Yuzawa, M., Mori, R., Haruyama, M. & Tanaka, K. Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol. 91, e474\u2013481, https:\/\/doi.org\/10.1111\/aos.12110 (2013).","journal-title":"Acta Ophthalmol."},{"key":"65346_CR19","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1167\/iovs.14-16236","volume":"56","author":"G Coscas","year":"2015","unstructured":"Coscas, G. et al. Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 56, 3187\u20133195, https:\/\/doi.org\/10.1167\/iovs.14-16236 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"65346_CR20","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1136\/bjophthalmol-2014-305059","volume":"98","author":"CS Tan","year":"2014","unstructured":"Tan, C. S., Ngo, W. K., Lim, L. W. & Lim, T. H. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes. Br. J. Ophthalmol. 98, 1528\u20131533, https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305059 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"65346_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung, C. M. G. et al. Pachychoroid disease. Eye 33, 14\u201333, https:\/\/doi.org\/10.1038\/s41433-018-0158-4 (2019).","journal-title":"Eye"},{"key":"65346_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","volume":"155","author":"H Koizumi","year":"2013","unstructured":"Koizumi, H., Yamagishi, T., Yamazaki, T. & Kinoshita, S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am. J. Ophthalmol. 155, 305\u2013313 e301, https:\/\/doi.org\/10.1016\/j.ajo.2012.07.018 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi, Y. et al. Choroidal Vascular Hyperpermeability as a Predictor of Treatment Response for Polypoidal Choroidal Vasculopathy. Retina 38, 1509\u20131517, https:\/\/doi.org\/10.1097\/IAE.0000000000001758 (2018).","journal-title":"Retina"},{"key":"65346_CR24","doi-asserted-by":"publisher","first-page":"e0212055","DOI":"10.1371\/journal.pone.0212055","volume":"14","author":"K Azuma","year":"2019","unstructured":"Azuma, K. et al. The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. Plos one 14, e0212055, https:\/\/doi.org\/10.1371\/journal.pone.0212055 (2019).","journal-title":"Plos one"},{"key":"65346_CR25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","volume":"156","author":"HJ Cho","year":"2013","unstructured":"Cho, H. J. et al. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 156, 1192\u20131200 e1191, https:\/\/doi.org\/10.1016\/j.ajo.2013.07.001 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep16204","volume":"5","author":"M Miyake","year":"2015","unstructured":"Miyake, M. et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci. Rep. 5, 16204, https:\/\/doi.org\/10.1038\/srep16204 (2015).","journal-title":"Sci. Rep."},{"key":"65346_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","volume":"59","author":"Y Nomura","year":"2015","unstructured":"Nomura, Y. & Yanagi, Y. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Jpn. J. Ophthalmol. 59, 261\u2013265, https:\/\/doi.org\/10.1007\/s10384-015-0387-z (2015).","journal-title":"Jpn. J. Ophthalmol."},{"key":"65346_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41433-018-0228-7","volume":"33","author":"J Baek","year":"2019","unstructured":"Baek, J., Lee, J. H., Jeon, S. & Lee, W. K. Choroidal morphology and short-term outcomes of combination photodynamic therapy in polypoidal choroidal vasculopathy. Eye 33, 419\u2013427, https:\/\/doi.org\/10.1038\/s41433-018-0228-7 (2019).","journal-title":"Eye"},{"key":"65346_CR29","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/IAE.0000000000001776","volume":"38","author":"KYC Teo","year":"2018","unstructured":"Teo, K. Y. C. et al. Comparison of Optical Coherence Tomography Angiographic Changes after Anti-Vascular Endothelial Growth Factor Therapy Alone or in Combination with Photodynamic Therapy in Polypoidal Choroidal Vasculopathy. Retina 38, 1675\u20131687, https:\/\/doi.org\/10.1097\/IAE.0000000000001776 (2018).","journal-title":"Retina"},{"key":"65346_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08276-4","volume":"7","author":"DSW Ting","year":"2017","unstructured":"Ting, D. S. W. et al. Choroidal Remodeling in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-month Prospective Study. Sci. Rep. 7, 7868, https:\/\/doi.org\/10.1038\/s41598-017-08276-4 (2017).","journal-title":"Sci. Rep."},{"key":"65346_CR31","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1097\/IAE.0000000000001427","volume":"37","author":"Y Sakurada","year":"2017","unstructured":"Sakurada, Y. et al. Choroidal Thickness as a Prognostic Factor of Photodynamic Therapy with Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy. Retina 37, 1866\u20131872, https:\/\/doi.org\/10.1097\/IAE.0000000000001427 (2017).","journal-title":"Retina"},{"key":"65346_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2015.09.032","volume":"161","author":"Y Kuroda","year":"2016","unstructured":"Kuroda, Y. et al. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. Am. J. Ophthalmol. 161, 94\u2013103 e101, https:\/\/doi.org\/10.1016\/j.ajo.2015.09.032 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","volume":"167","author":"AG Marneros","year":"2005","unstructured":"Marneros, A. G. et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167, 1451\u20131459, https:\/\/doi.org\/10.1016\/S0002-9440(10)61231-X (2005).","journal-title":"Am. J. Pathol."},{"key":"65346_CR34","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A. E. & D\u2019Amore, P. A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl Acad. Sci. USA 106, 18751\u201318756, https:\/\/doi.org\/10.1073\/pnas.0905010106 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65346_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.oret.2017.05.013","volume":"2","author":"T Hiroe","year":"2018","unstructured":"Hiroe, T. & Kishi, S. Dilatation of Asymmetric Vortex Vein in Central Serous Chorioretinopathy. Ophthalmol. Retina 2, 152\u2013161, https:\/\/doi.org\/10.1016\/j.oret.2017.05.013 (2018).","journal-title":"Ophthalmol. Retina"},{"key":"65346_CR36","doi-asserted-by":"publisher","first-page":"e0206646","DOI":"10.1371\/journal.pone.0206646","volume":"13","author":"S Kishi","year":"2018","unstructured":"Kishi, S. et al. Geographic filling delay of the choriocapillaris in the region of dilated asymmetric vortex veins in central serous chorioretinopathy. Plos one 13, e0206646, https:\/\/doi.org\/10.1371\/journal.pone.0206646 (2018).","journal-title":"Plos one"},{"key":"65346_CR37","first-page":"198","volume":"119","author":"NM Bressler","year":"2001","unstructured":"Bressler, N. M. & Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study, G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 119, 198\u2013207 (2001).","journal-title":"Arch. Ophthalmol."},{"key":"65346_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study, G.","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study, G. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2013verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. 131, 541\u2013560, https:\/\/doi.org\/10.1016\/s0002-9394(01)00967-9 (2001).","journal-title":"Am. J. Ophthalmol."},{"key":"65346_CR39","first-page":"417","volume":"109","author":"Japanese Study Group of Polypoidal Choroidal, V.","year":"2005","unstructured":"Japanese Study Group of Polypoidal Choroidal, V. [Criteria for diagnosis of polypoidal choroidal vasculopathy]. Nippon. Ganka Gakkai Zasshi 109, 417\u2013427 (2005).","journal-title":"Nippon. Ganka Gakkai Zasshi"},{"key":"65346_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1890\/13-1066.1","volume":"95","author":"KP Burnham","year":"2014","unstructured":"Burnham, K. P. & Anderson, D. R. P values are only an index to evidence: 20th- vs. 21st-century statistical science. Ecology 95, 627\u2013630 (2014).","journal-title":"Ecology"},{"key":"65346_CR41","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1214\/12-AOS1003","volume":"40","author":"RJ Tibshirani","year":"2012","unstructured":"Tibshirani, R. J. & Taylor, J. Degrees of freedom in lasso problems. Ann. Statist. 40, 1198\u20131232, https:\/\/doi.org\/10.1214\/12-AOS1003 (2012).","journal-title":"Ann. Statist."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65346-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:54:39Z","timestamp":1670327679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65346"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65346-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8337"}}